Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06829498 · ClinicalTrials.gov registry record · Phase 2
BCAAs in Concussion 2.0
A Phase 2 study of Concussion, Brain and Concussion, Mild, sponsored by Akiva Cohen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06829498: Recruiting Phase 2 study of Concussion, Brain and Concussion, Mild, sponsored by Akiva Cohen.
NCT06829498 is a Phase 2 study of Concussion, Brain and Concussion, Mild that is actively recruiting participants, run by Akiva Cohen. The registered enrollment target is 150 participants, below the 177-participant average among 20 other Concussion, Brain trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06829498, a Phase 2 study of Concussion, Brain and Concussion, Mild, is actively recruiting participants, sponsored by Akiva Cohen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.
Primary Outcome
This will be determined by research staff at in person visits by the return to baseline symptom levels along with participant self-report of feeling \> 90% back to normal. Percentage recovered at 28 days will be compared between placebo and control group by chi-square testing.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BCAA
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT06829498 shows while recruiting
NCT06829498 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 177-participant average among 20 other Concussion, Brain trials with a reported enrollment target (15% lower).
The record links to 3 conditions, with Concussion, Brain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06829498 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06829498 about?
NCT06829498 is a clinical study titled "BCAAs in Concussion 2.0". This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery...
What is the current status of trial NCT06829498?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-04-01. Estimated completion is 2026-08.
What conditions does trial NCT06829498 study?
This clinical trial studies the following conditions: Concussion, Brain, Concussion, Mild, Concussion.
What interventions are being tested in trial NCT06829498?
The interventions under investigation include: Placebo (OTHER), BCAA (DRUG).
Who is sponsoring clinical trial NCT06829498?
This trial is sponsored by Akiva Cohen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06829498 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Concussion, Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06829498's enrollment target sits among peer trials
150 9th of 20 higher than 12 of 20 other Concussion, Brain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Concussion, Brain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Personalized Brain Stimulation to Treat Chronic Concussive Symptoms
RECRUITING · Phase 2
-
Modulating Exercise Dosage to Improve Concussion Recovery
RECRUITING · Phase 2
-
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
RECRUITING · Phase 2
-
Growth Hormone Replacement Therapy for Retried Professional Football Players
RECRUITING · Phase 2
-
Risk Stratification in Children With Concussion
RECRUITING
-
Combined Neuromodulation and Cognitive Training for Post-mTBI Depression
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI